NDAORALTABLET, DELAYED RELEASE
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZUNVEYL (benzgalantamine) is an oral delayed-release tablet approved by the FDA on July 26, 2024, developed by AlphaCognition. The specific indication(s) and mechanism of action are not yet disclosed in available data. Patient populations and therapeutic applications will become clearer as clinical and commercial information expands.
Growth19.2 years to LOE
Early-stage growth asset with minimal competitive pressure suggests opportunity for rapid team expansion and market development roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZUNVEYL is a newly approved growth-stage asset with minimal current job postings but significant upside potential as commercial infrastructure scales. Long-term care positioning suggests specialized sales and account management roles will be primary near-term opportunities.
Long Term Care Account Manager
Commercial
Worked on ZUNVEYL at AlphaCognition? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.